secwatch.observer — SEC 8-K summary
======================================

Issuer:     ArriVent BioPharma, Inc. (AVBP)
CIK:        0001868279
Form:       8-K
Filed at:   2026-03-05T23:59:59+00:00
Accession:  0001104659-26-024112
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ArriVent reports FY2025 net loss of $166.3M; cash of $312.8M funds into 3Q 2027
-------------------------------------------------------------------------------

- Cash and investments of $312.8M as of Dec 31, 2025; expected to fund operations into 3Q 2027.
- Net loss $166.3M in FY2025 vs $80.5M in FY2024; R&D expenses $153.4M (incl. one-time payment to Lepu).
- Topline pivotal Phase 3 data for firmonertinib in first-line EGFR exon20ins NSCLC expected mid-2026.
- Phase 3 ALPACCA study for firmonertinib in EGFR PACC mutant NSCLC dosed first patient in Dec 2025.
- ADC lead ARR-217 in Phase 1 dose escalation; IND clearance received; first patient dosed March 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1868279/000110465926024112/0001104659-26-024112-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1868279/000110465926024112/avbp-20260305x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-024112

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer